Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa.